Evaluation of MAGE-A expression and grade of dysplasia for predicting malignant progression of oral leukoplakia

International Journal of Oncology

Volumn 41, Issue 3, 2012, Pages 1085-1093

  Ries, Jutta ^a   Agaimy, Abbas ^a   Vairaktaris, Elefterios ^b   Kwon, Yeeun ^a   Neukam, Friedrich W ^a   Strassburg, Lei H ^a   Nkenke, Emeka ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Melanoma associated antigen A expression; Oral squamous cell carcinoma; Real time RT PCR; Risk assessment of oral leukoplakia

Indexed keywords

MAGE A PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE COURSE; DYSPLASIA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERPLASIA; LEUKOPLAKIA, ORAL; MALE; MELANOMA-SPECIFIC ANTIGENS; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84864999830     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1532     Document Type: Article

References (42)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Lung T, Tascau OC, Almasan HA and Mureşan O: Head and neck cancer, treatment, evolution and post therapeutic survival - Part 2: a decade's results 1993-2002. J Craniomaxillofac Surg 35: 126-131, 2007.
3. Gondos A, Arndt V, Holleczek B, et al: Cancer survival in Germany and the United States at the beginning of the 21st century: an up-to-date comparison by period analysis. Int J Cancer 121: 395-400, 2007. (Pubitemid 46917710)
4. Hunter KD, Parkinson EK and Harrison PR: Profiling early head and neck cancer. Nat Rev Cancer 5: 127-135, 2005. (Pubitemid 40220338)
5. Warnakulasuriya S, Johnson NW and van der Waal I: Nomenclature and classification of potentially malignant disorders of the mucosa. J Oral Pathol Med 36: 575-580, 2007. (Pubitemid 47609807)
6. Fleskens S and Slootweg P: Grading systems in head and neck dysplasia: their prognostic value, weaknesses and utility. Head Neck Oncol 1: 11-18, 2009.
7. Warnakulasuriya S, Reibel J, Bouquot J and Dabelsteen E: Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med 37: 127-133, 2008. (Pubitemid 351178405)
8. Van der Waal I: Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol 45: 317-323, 2009.
9. Pindborg JJ, Reichart PA, Smith CJ and van der Waal I: World Health Organization: Histological Typing of Cancer and Precancer of the Oral Mucosa. Vol. 14. Springer-Verlag, Berlin, pp47-62, 1997.
10. Reibel J: Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med 14: 47-62, 2003.
11. Holmstrup P, Vedtofte P, Reibel J and Stoltze K: Oral premalignant lesions: is a biopsy reliable? J Oral Pathol Med 36: 262-266, 2007. (Pubitemid 46632607)
12. Fleskens SA, Bergshoeff VE, Voogd AC, et al: Interobserver variability of laryngeal mucosal premalignant lesions: a histopathological evaluation. Mod Pathol 24: 892-898, 2011.
13. Brennan M, Migliorati CA, Lockhart PB, et al: Management of oral epithelial dysplasia: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103 (Suppl 19): e1-e12, 2007.
14. Warnakulasuriya S: Lack of molecular markers to predict malignant potential of oral precancer. J Pathol 190: 407-409, 2000.
15. Ha PK, Chang SS, Glazer CA, et al: Molecular techniques and genetic alterations in head and neck cancer. Oral Oncol 45: 335-339, 2009.
16. Pitiyage G, Tilakaratne WM, Tavassoli M and Warnakulasuriya S: Molecular markers in oral epithelial dysplasia: review. J Oral Pathol Med 38: 737-752, 2009.
17. Nasser W, Flechtenmacher C, Holzinger D, et al: Aberrant expression of p53, p16(INK4a) and Ki-67 as basic biomarker for malignant progression of oral leukoplakias. J Oral Pathol Med 40: 629-635, 2011.
18. Vairaktaris E, Yapijakis C, Derka S, et al: Association of platelet glycoprotein Ia polymorphism with minor increase of risk for oral cancer. Eur J Surg Oncol 32: 455-457, 2006. (Pubitemid 44287669)
19. Vairaktaris E, Yapijakis C, Yiannopoulos A, et al: Strong association of the tissue inhibitor of metalloproteinase-2 polymorphism with an increased risk of oral squamous cell carcinoma in Europeans. Oncol Rep 17: 963-968, 2007.
20. Yapijakis C, Vairaktaris E, Vassiliou S, et al: The low VEGF production allele of the +936C/T polymorphism is strongly associated with increased risk for oral cancer. J Cancer Res Clin Oncol 133: 787-791, 2007. (Pubitemid 47319247)
21. Jungbluth AA, Busam KJ, Kolb D, et al: Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer 85: 460-465, 2000. (Pubitemid 30075121)
22. Muller-Richter UD, Dowejko A, Peters S, et al: MAGE-A antigens in patients with primary oral squamous cell carcinoma. Clin Oral Investig 14: 291-296, 2010.
23. Ries J, Mollaoglu N, Toyoshima T, et al: A novel multiple-marker method for the early diagnosis of oral squamous cell carcinoma. Dis Markers 27: 75-84, 2009.
24. Krauss E, Rauthe S, Gattenlohner S, et al: MAGE-A antigens in lesions of the oral mucosa. Clin Oral Investig 15: 315-320, 2011.
25. Metzler P, Mollaoglu N, Schwarz S, et al: MAGE-A as a novel approach in the diagnostic accuracy of oral squamous cell cancer: a case report. Head Neck Oncol 39: 1-6, 2009.
26. Ries J, Ponader S, Mollaoglu N, et al: Early findings of a novel established molecular diagnostic technique for the prediction of malignant transformation in leukoplakia. Mol Med Rep 2: 947-952, 2009.
27. Mecklenburg I, Weckermann D, Zippelius A, et al: A multi-marker real-time RT-PCR for MAGE-A gene expression allows sensitive detection and quantification of the minimal systemic tumor load in patients with localized cancer. J Immunol Methods 323: 180-193, 2007. (Pubitemid 46890967)
28. Scheifele C and Reichart PA: Is there a natural limit of the transformation rate of oral leukoplakia? Oral Oncol 39: 470-475, 2003. (Pubitemid 36579114)
29. Scheifele C and Reichart PA: Oral leukoplakia in manifest squamous epithelial carcinoma. A clinical prospective study of 101 patients. Mund Kiefer Gesichtschir 2: 326-330, 1998 (In German).
30. Rethman MP, Carpenter W, Cohen EE, et al: Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. J Am Dent Assoc 141: 509-520, 2010.
31. Oliveira LR and Ribeiro-Silva A: Prognostic significance of immunohistochemical biomarkers in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 40: 298-307, 2011.
32. Ehrlich M: DNA methylation in cancer: too much, but also too little. Oncogene 21: 5400-5413, 2002.
33. Diez-Perez R, Campo-Trapero J, Cano-Sanchez J, et al: Methylation in oral cancer and pre-cancerous lesions (Review). Oncol Rep 25: 1203-1209, 2011.
34. Simpson AJ, Caballero OL, Jungbluth A, et al: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5: 615-625, 2005. (Pubitemid 41081387)
35. De Smet C, Loriot A and Boon T: Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells. Mol Cell Biol 24: 4781-4790, 2004. (Pubitemid 38668044)
36. Ries J, Schultze-Mosgau S, Neukam F, et al: Investigation of the expression of melanoma antigen-encoding genes (MAGE-A1 to -A6) in oral squamous cell carcinomas to determine potential targets for gene-based cancer immunotherapy. Int J Oncol 26: 817-824, 2005.
37. Ries J, Vairaktaris E, Mollaoglu N, et al: Expression of melanoma-associated antigens in oral squamous cell carcinoma. J Oral Pathol Med 37: 88-93, 2008.
38. Sang M, Lian Y, Zhou X and Shan B: MAGE-A family: Attractive targets for cancer immunotherapy. Vaccine 29: 8496-8500, 2011.
39. Atanackovic D, Blum I, Cao Y, et al: Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma. Cancer Biol Ther 5: 1218-1225, 2006. (Pubitemid 44772241)
40. Rapidis AD and Wolf GT: Immunotherapy of head and neck cancer: current and future considerations. J Oncol 2009: 346345, 2009.
41. Lingen MW, Kalmar JR, Karrison T and Speight PM: Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol 44: 10-22, 2008. (Pubitemid 350258631)
42. Mollaoglu N, Metzler P, Zenk J, et al: Prediction of recurrence using exfoliative cytology and melanoma-associated antigen-A mRNA analysis following wide excision of oral squamous cell carcinoma: short report. Cytopathology 22: 387-391, 2011.